5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.

Archiv der Pharmazie
Khaled El-AdlFatma M A Shoman

Abstract

A novel series of 5-(4-methoxybenzylidene)thiazolidine-2,4-dione derivatives, 5a-g and 7a-f, was designed, synthesized, and evaluated for their anticancer activity against HepG2, HCT116, and MCF-7 cells. HepG2 and HCT116 were the most sensitive cell lines to the influence of the new derivatives. In particular, compounds 7f, 7e, 7d, and 7c were found to be the most potent derivatives of all the tested compounds against the HepG2, HCT116, and MCF-7 cancer cell lines. Compound 7f (IC50  = 6.19 ± 0.5, 5.47 ± 0.3, and 7.26 ± 0.3 µM, respectively) exhibited a higher activity than sorafenib (IC50  = 9.18 ± 0.6, 8.37 ± 0.7, and 5.10 ± 0.4 µM, respectively) against HepG2 and MCF-7, cells but a lower activity against HCT116 cancer cells, respectively. Also, this compound displayed a higher activity than doxorubicin (IC50  = 7.94 ± 0.6, 8.07 ± 0.8, and 6.75 ± 0.4 µM, respectively) against HepG2 and MCF-7 cells, but nearly the same activity against HCT116 cells, respectively. All derivatives, 5a-g and 7a-f, were evaluated for their inhibitory activities against vascular endothelial growth factor receptor-2 (VEGFR-2). Among them, compound 7f was found to be the most potent derivative that inhibited VEGFR-2 at an IC50 value of 0.12 ± 0.02 µM...Continue Reading

References

Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Nov 5, 2005·Nature Clinical Practice. Oncology·Giampietro GaspariniNapoleone Ferrara
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Oct 4, 2006·Nature Reviews. Drug Discovery·Scott WilhelmSusan Kelley
Jul 14, 2007·Current Medicinal Chemistry·Cláudio Viegas-JuniorCarlos Alberto Manssour Fraga
May 9, 2008·The New England Journal of Medicine·Robert S Kerbel
Jan 14, 2009·Journal of Molecular Graphics & Modelling·Qing-Qing XieSheng-Yong Yang
Jun 3, 2009·Nature Reviews. Gastroenterology & Hepatology·Hans Christian SpangenbergHubert E Blum
Sep 28, 2010·European Journal of Medicinal Chemistry·Kyungik LeeYangmee Kim
Mar 1, 2011·Bioorganic & Medicinal Chemistry Letters·Antonio GarofaloPatrick Depreux
Jun 30, 2011·The Biochemical Journal·Sina KochLena Claesson-Welsh
Sep 20, 2011·Cell·Michael PotentePeter Carmeliet
Nov 11, 2011·International Journal of Molecular Sciences·Andreas PircherMichael Medinger
Feb 4, 2012·European Journal of Medicinal Chemistry·Young Mi HaHae Young Chung
Mar 30, 2013·European Journal of Medicinal Chemistry·Romeo RomagnoliFrancisco Estévez
Nov 30, 2013·European Journal of Medicinal Chemistry·Lingaiah NagarapuJagadesh Nanubolu
Mar 7, 2014·Expert Opinion on Investigational Drugs·Hardik JoshiC S Ramaa
Feb 10, 2011·ACS Medicinal Chemistry Letters·Timothy I RichardsonJeffrey A Dodge
Jan 27, 2015·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Radhe Shyam BahareSupaporn Seetaha
May 16, 2015·Trends in Pharmacological Sciences·Peng WuMads H Clausen
Nov 23, 2015·European Journal of Medicinal Chemistry·Sahar M Abou-SeriDalal A Abou El Ella
Apr 27, 2017·Scientific Reports·Valentina CappelloMauro Gemmi
Dec 10, 2017·Chemistry Central Journal· SuchetaPrabhakar Kumar Verma
Jan 24, 2020·Frontiers in Chemistry·Zarko GagicKatarina Nikolic

❮ Previous
Next ❯

Citations

Apr 4, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nadipolla Naresh ReddyPuchakayala Muralidhar Reddy
May 8, 2021·Bioorganic & Medicinal Chemistry·Abdelfattah HassanGamal El-Din A Abuo-Rahma
Oct 2, 2021·Archiv der Pharmazie·Khaled El-AdlIbrahim H Eissa

❮ Previous
Next ❯

Related Concepts